Effect of low-dose aspirin on cancer chemoprevention in Japanese patients with diabetes
| Project/Area Number |
17K18022
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Epidemiology and preventive medicine
Metabolomics
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
Okada Sadanori 奈良県立医科大学, 医学部, 助教 (50624780)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Keywords | 糖尿病 / 癌 / 低用量アスピリン |
|---|
| Outline of Final Research Achievements |
It has been reported that diabetes increases not only cardiovascular diseases, such as myocardial infarction and stroke, but also various cancers. Low-dose aspirin therapy has been conventionally used to prevent cardiovascular disease, but recently, attention has also been paid to the effect of aspirin on cancer chemoprevention, especially colorectal cancer.
In this study, we analyzed whether low-dose aspirin could reduce cancer incidence in patients with diabetes. We employed the JPAD study cohort, which include 2,536 Japanese patients with type 2 diabetes. During the median follow-up period of 12.3 years, 358 patients developed cancer. But low-dose aspirin therapy did not reduce cancer development. We plan to continue research and analysis using this cohort.
|
| Academic Significance and Societal Importance of the Research Achievements |
日本では2人に1人が癌に罹患し、3人に1人が癌で死亡している。本研究において、糖尿病患者が癌のハイリスク集団であることが改めて示された。残念ながら、本研究では日本人2型糖尿病において低用量アスピリン療法の発癌抑制効果は示すことができなかったが、発癌に関する12年を超える糖尿病コホートを構築することできた。今後もJPAD研究コホートを用いて、糖尿病患者における薬剤や合併症と発癌に関する研究・報告を行なっていく予定である。
|
Report
(4 results)
Research Products
(3 results)
